Table 2. Efficacy of crizotinib treatment.
| Efficacy | All patients (n=120) | No baseline BM (n=82) | Baseline BM (n=38) | P |
|---|---|---|---|---|
| Tumor response, n (%) | ||||
| CR | 0 (0) | 0 (0) | 0 (0) | |
| PR | 83 (69.2) | 57 (69.5) | 26 (68.4) | |
| SD | 25 (20.8) | 15 (18.3) | 10 (26.3) | |
| PD | 12 (10.0) | 10 (12.2) | 2 (5.3) | |
| ORR, % | 69.2 | 69.5 | 68.4 | 0.904 |
| DCR, % | 90 | 87.8 | 94.7 | 0.335 |
| PFS, median (95% CI) (months) | 8.5 (6.8-10.1) | 10.0 (7.6-12.5) | 7.0 (6.4-7.6) | 0.021 |
| OS from the time of stage IV diagnosis, median (95% CI) (months) | 34.9 (28.4-41.5) | 34.2 (26.7-41.6) | 35.5 (24.4-46.7) | 0.861 |
CR, complete response; DCR, disease control rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; ORR, objective response rate; OS, overall survival.